Logo image of COGT

COGENT BIOSCIENCES INC (COGT) Stock Fundamental Analysis

NASDAQ:COGT - Nasdaq - US19240Q2012 - Common Stock - Currency: USD

5.87  +0.24 (+4.26%)

After market: 5.87 0 (0%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to COGT. COGT was compared to 566 industry peers in the Biotechnology industry. The financial health of COGT is average, but there are quite some concerns on its profitability. COGT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year COGT has reported negative net income.
COGT had a negative operating cash flow in the past year.
COGT had negative earnings in each of the past 5 years.
COGT had a negative operating cash flow in each of the past 5 years.
COGT Yearly Net Income VS EBIT VS OCF VS FCFCOGT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50M -100M -150M -200M

1.2 Ratios

COGT has a Return On Assets of -61.43%. This is in the lower half of the industry: COGT underperforms 60.60% of its industry peers.
Looking at the Return On Equity, with a value of -78.59%, COGT is in line with its industry, outperforming 52.65% of the companies in the same industry.
Industry RankSector Rank
ROA -61.43%
ROE -78.59%
ROIC N/A
ROA(3y)-46.38%
ROA(5y)-55%
ROE(3y)-54.41%
ROE(5y)-67.93%
ROIC(3y)N/A
ROIC(5y)N/A
COGT Yearly ROA, ROE, ROICCOGT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

COGT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
COGT Yearly Profit, Operating, Gross MarginsCOGT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -500 -1K -1.5K -2K

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, COGT has more shares outstanding
Compared to 5 years ago, COGT has more shares outstanding
COGT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
COGT Yearly Shares OutstandingCOGT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
COGT Yearly Total Debt VS Total AssetsCOGT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -0.20, we must say that COGT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of COGT (-0.20) is better than 63.07% of its industry peers.
There is no outstanding debt for COGT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.2
ROIC/WACCN/A
WACCN/A
COGT Yearly LT Debt VS Equity VS FCFCOGT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M

2.3 Liquidity

A Current Ratio of 5.32 indicates that COGT has no problem at all paying its short term obligations.
COGT has a Current ratio (5.32) which is in line with its industry peers.
A Quick Ratio of 5.32 indicates that COGT has no problem at all paying its short term obligations.
COGT has a Quick ratio of 5.32. This is comparable to the rest of the industry: COGT outperforms 58.83% of its industry peers.
Industry RankSector Rank
Current Ratio 5.32
Quick Ratio 5.32
COGT Yearly Current Assets VS Current LiabilitesCOGT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.92% over the past year.
EPS 1Y (TTM)17.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, COGT will show a very strong growth in Earnings Per Share. The EPS will grow by 20.03% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-13.54%
EPS Next 2Y1.14%
EPS Next 3Y16.38%
EPS Next 5Y20.03%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
COGT Yearly Revenue VS EstimatesCOGT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M 1B
COGT Yearly EPS VS EstimatesCOGT Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for COGT. In the last year negative earnings were reported.
Also next year COGT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
COGT Price Earnings VS Forward Price EarningsCOGT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
COGT Per share dataCOGT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2

4.3 Compensation for Growth

A more expensive valuation may be justified as COGT's earnings are expected to grow with 16.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.14%
EPS Next 3Y16.38%

More info and screens

0

5. Dividend

5.1 Amount

COGT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COGENT BIOSCIENCES INC

NASDAQ:COGT (5/2/2025, 8:00:01 PM)

After market: 5.87 0 (0%)

5.87

+0.24 (+4.26%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-25 2025-02-25/bmo
Earnings (Next)05-13 2025-05-13/bmo
Inst Owners110.27%
Inst Owner Change0.02%
Ins Owners0.04%
Ins Owner Change5.66%
Market Cap668.30M
Analysts82.22
Price Target16.42 (179.73%)
Short Float %12.71%
Short Ratio10.51
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)34.63%
Min EPS beat(2)-10.87%
Max EPS beat(2)80.14%
EPS beat(4)1
Avg EPS beat(4)12.23%
Min EPS beat(4)-17.75%
Max EPS beat(4)80.14%
EPS beat(8)2
Avg EPS beat(8)1.89%
EPS beat(12)3
Avg EPS beat(12)-1.7%
EPS beat(16)4
Avg EPS beat(16)-3.92%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.83%
PT rev (3m)-4.17%
EPS NQ rev (1m)-2.52%
EPS NQ rev (3m)-3.01%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.61
P/tB 2.61
EV/EBITDA N/A
EPS(TTM)-1.97
EYN/A
EPS(NY)-2.24
Fwd EYN/A
FCF(TTM)-1.37
FCFYN/A
OCF(TTM)-1.35
OCFYN/A
SpS0
BVpS2.25
TBVpS2.25
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.43%
ROE -78.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.38%
ROA(5y)-55%
ROE(3y)-54.41%
ROE(5y)-67.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 123.17%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.32
Quick Ratio 5.32
Altman-Z -0.2
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)695.5%
Cap/Depr(5y)417.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%80.95%
EPS Next Y-13.54%
EPS Next 2Y1.14%
EPS Next 3Y16.38%
EPS Next 5Y20.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-32.58%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-6.39%
EBIT Next 3Y-1.25%
EBIT Next 5Y4.81%
FCF growth 1Y-24.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.49%
OCF growth 3YN/A
OCF growth 5YN/A